verified from the grantee records to support the information outlined in the FSR.

Failure to submit required reports within the time allowed may result in suspension or termination of an active grant, withholding of additional awards for the project, or other enforcement actions such as withholding of payments or converting to the reimbursement method of payment. Continued failure to submit required reports may result in one or both of the following: (1) The imposition of special award provisions; and (2) the non-funding or non-award of other eligible projects or activities. This applies whether the delinquency is attributable to the failure of the grantee organization or the individual responsible for preparation of the reports.

C. FY 2007 and FY 2008 Single Audit Reports (OMB A–133)

Applicants who have an active SDPI grant are required to be up-to-date in the submission of required audit reports. These are the annual financial audit reports required by OMB A–133, audits of State, local governments, and non-profit organizations that are submitted. Documentation of (or proof of submission) of current FY 2007 and FY 2008 Financial Audit Reports is mandatory. Acceptable forms of documentation include: e-mail confirmation from FAC that audits were submitted; or face sheets from audit reports. Face sheets can be found on the FAC Web site: *http://harvester.census.gov/fac/dissem/accessoptions.html?submit=Retrieve+Records.*

Telecommunication for the hearing impaired is available at: TTY (301) 443–6394.

VII. Agency Contacts

- For Grants Budget Management, contact:
- Denise Clark, Lead Grants Management Specialist, DGO (*denise.clark@ihs.gov*), Division of Grants Operations, 801 Thompson Avenue, TMP, Suite 360, Rockville, MD 20852. (301) 443–5204.
- For Grants.gov electronic application process, contact:
- Tammy Bagley, Grants Policy, DGP (*tammy.bagley@ihs.gov*), (301) 443–5204. Grants Policy Web site: *http://www.ihs.gov/NonMedicalPrograms/gogp/index.cfm?module=gogp_funding.*
- For programmatic questions, contact:
- Merle Mike, Program Assistant, DDTP (*merle.mike@ihs.gov*), (505) 248–4182.
- Lorraine Valdez, Deputy Director, DDTP (*s.lorraine.valdez@ihs.gov*), (505) 248–4182.
- Area Diabetes Consultants Web site: *http://www.ihs.gov/MedicalPrograms/diabetes/index.cfm?module=peopleADCDirectory.*

Dated: December 22, 2009.

Yvette Roubideaux,

Director, Indian Health Service.

[FR Doc. 2010–149 Filed 1–8–10; 8:45 am]

BILLING CODE 4165–16–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2009–N–0606]

General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee; Amendment of Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an amendment to the notice of a meeting of the General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee. This meeting was announced in the **Federal Register** of November 17, 2009 (74 FR 59194). The amendment is being made to reflect a change in the *Contact Person* and *Procedure* portions of the document, and to provide notice of the availability of a docket for public comment. There are no other changes.

FOR FURTHER INFORMATION CONTACT: Margaret McCabe-Janicki, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., White Oak 66, rm. 1535, Silver Spring, MD 20993, 301–796–7029, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 3014512519. Please call the Information Line for up-to-date information on this meeting.

SUPPLEMENTARY INFORMATION: In FR Doc. E9–27491, appearing on page 59194, in the **Federal Register** of Tuesday, November 17, 2009, the following corrections are made:

1. On page 59194, in the second column, under *Contact Person*, the first six lines "Peter L. Hudson, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., White Oak 66, rm. 3618, Silver Spring, MD 20993, 301–796–6440 or FDA Advisory" are removed and replaced with "Margaret McCabe-Janicki, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Avenue., White Oak 66, rm. 1535, Silver Spring, MD 20993, 301–796–7029, or FDA Advisory".

2. On page 59194, in the third column, a *Comments* portion is added before the *Agenda* portion of the document to read: "*Comments*: FDA is opening a docket for public comment on this document. The docket number is FDA–2009–N–0606. The docket will open for public comment on January 11, 2010. The docket will close on March 19, 2010. Interested persons may submit electronic or written comments regarding this document. Submit electronic comments to *http://www.regulations.gov*. Submit written comments to the Division of Dockets Management, Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit a single copy of electronic comments or two paper copies of any mailed comments, except that individuals may submit one paper copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday."

3. On pages 59194 and 59195, beginning on page 59194 in the third column, under *Procedure*, the year "2009" is changed to read "2010" everywhere that it appears.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.

Dated: January 5, 2010.

David Dorsey,

Acting Deputy Commissioner for Policy, Planning and Budget.

[FR Doc. 2010–172 Filed 1–8–10; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2009–N–0664]

Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.